For example, the protein kinase inhibitor imatinib (Gleevec) was designed to treat chronic myelogenous leukemia (CML) based on knowledge of the causative molecular defect—translocation and dys-regulated BCR–ABL kinase. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.